Diagnostic Mycology Laboratories Should Have a Central Role for the Management of Fungal Disease.
HIV
Latin America
cryptococcosis
histoplasmosis
opportunistic infections
public health
tuberculosis
Journal
Journal of fungi (Basel, Switzerland)
ISSN: 2309-608X
Titre abrégé: J Fungi (Basel)
Pays: Switzerland
ID NLM: 101671827
Informations de publication
Date de publication:
08 Dec 2022
08 Dec 2022
Historique:
received:
16
11
2022
revised:
03
12
2022
accepted:
06
12
2022
entrez:
22
12
2022
pubmed:
23
12
2022
medline:
23
12
2022
Statut:
epublish
Résumé
The absence of awareness of fungal diseases as part of the differential diagnosis in at-risk populations has severe consequences. Here, we show how the active role of laboratories can improve patients’ survival. Recently, major advances have been made in non-culture-based assays for fungal diseases, improving accuracy and turnaround time. Furthermore, with the introduction of proficiency control systems, laboratories are an easily monitored environment with good analytical accuracy. Diagnostic packages for opportunistic infections can overcome many deficiencies caused by the absence of awareness. In Guatemala, to make diagnosis accessible, we set up a diagnostic laboratory hub (DLH) providing screening for cryptococcosis, histoplasmosis and tuberculosis to a network of 13 healthcare facilities attending people living with HIV (PLWHIV). In two years, we screened 2127 newly HIV-diagnosed patients. The frequency of opportunistic infections was 21%, rising to 30.3% in patients with advanced HIV disease (<200 CD4); 8.1% of these patients had more than one infection. With the implementation of this diagnostic package, mortality decreased by 7%, a key goal of many public health interventions. Screening for serious infection in high-risk populations can partially overcome training or experiential deficiencies among clinicians for life-threatening fungal diseases.
Identifiants
pubmed: 36547618
pii: jof8121285
doi: 10.3390/jof8121285
pmc: PMC9787327
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Tuberc Lung Dis. 2021 Jul 1;25(7):537-546
pubmed: 34183098
JMIR Med Inform. 2020 Nov 18;8(11):e24163
pubmed: 33206057
J Infect Dis. 2002 Nov 1;186(9):1297-306
pubmed: 12402199
Microorganisms. 2021 Dec 16;9(12):
pubmed: 34946197
Am J Clin Pathol. 2021 May 18;155(6):823-831
pubmed: 33313667
Med Mycol. 2020 Apr 1;58(3):411-413
pubmed: 31290546
Blood. 2001 Mar 15;97(6):1604-10
pubmed: 11238098
Mycopathologia. 2020 Dec;185(6):947-958
pubmed: 32449054
Drugs. 2021 Oct;81(15):1703-1729
pubmed: 34626339
J Antimicrob Chemother. 2018 Dec 1;73(12):3488-3495
pubmed: 30252053
Eur Respir J. 2016 Jan;47(1):45-68
pubmed: 26699723
mBio. 2020 Apr 28;11(2):
pubmed: 32345637
Diagn Microbiol Infect Dis. 2014 Jul;79(3):322-7
pubmed: 24768294
Mycoses. 2018 Jul;61(7):477-484
pubmed: 29577447
Open Forum Infect Dis. 2019 Dec 15;7(1):ofz534
pubmed: 31915715
Clin Infect Dis. 2006 Jul 1;43(1):25-31
pubmed: 16758414
Lancet Infect Dis. 2018 Oct;18(10):1150-1159
pubmed: 30146320
Microorganisms. 2022 Jul 10;10(7):
pubmed: 35889106
AIDS. 2020 Sep 1;34(11):1625-1632
pubmed: 32694415
Clin Infect Dis. 2008 Aug 15;47(4):503-9
pubmed: 18611163
J Fungi (Basel). 2021 Apr 01;7(4):
pubmed: 33916153
Eur J Hosp Pharm. 2022 Mar;29(2):109-112
pubmed: 35190454
Euro Surveill. 2020 Mar;25(12):
pubmed: 32234118